Skip to content

Long-Term Debt at other companies

Viatris logo
ViatrisVTRS
$12.41B-12.4%
PTH
Pelthos Therapeutics Inc.PTHS
$26.36M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$45M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$72.06M+4.1%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$42.15B-8.7%

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept us-gaap:OtherLongTermDebtNoncurrent.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's long-term debt?
Scilex Holding Company (SCLX) reported long-term debt of $0 in Q1 2026.
What is the long-term trend for Scilex Holding Company's long-term debt?
Over 4 years (2021 to 2025), Scilex Holding Company's long-term debt has grown at a -25.3% compound annual growth rate (CAGR), from $72.04M to $22.48M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.